Münster, Germany, July 2016: the European Patent Office granted Cilian a new patent claiming recombinant production of monoclonal antibodies with its proprietary expression system CIPEX which is based on Ciliates.

Cilian already holds a number of patents covering its own therapeutic products manufactured with its technology platform. Patent number for this new coverage is EP 2542575 A1.